Skip to main content
Premium Trial:

Request an Annual Quote

Genelabs' CFO Quits; Aebersold Lands on Rosetta Biosoftware's SAB; Dolginow Leaves Gene Logic; Sequenom Hires Sales VP; and Others

NEW YORK (GenomeWeb News) – Genelabs Technologies this week said CFO Matthew Loar will resign on Sept. 1. The company said he has taken a job at an undisclosed biotech company.
 
James Smith, Genelabs’ president and CEO, will assume Loar’s duties until a permanent replacement is found.
 
In the same statement, Genelabs said it hired Peter Young to be its vice president of biology. Young comes to Genelabs from Celera Genomics, where he held the same position.

Expression Analysis has appointed the following people to its scientific advisory board: John Ryan, chief medical officer of AVEO Pharmaceuticals; Richard Hockett, medical fellow and director of genomic medicine at Eli Lilly; and Buzz Sztukowski, senior vice president of global marketing and strategic development at BioMerieux.

Gene Logic said Douglas Dolginow has left the company on Aug. 16. Dolginow was senior vice president of pharmacogenomics. He will continue to be employed by Gene Logic on a part-time basis as a fellow and senior advisor.

Sequenom has hired Michael Monko to be its new senior vice president of sales and marketing. Monko comes to Sequenom from Upstate. Chemicon where he most recently was vice president of sales. He has also had a 19-year stint with Invitrogen where he was a sales rep and later became senior director of sales force effectiveness.
 
Monko has an MBA from Babson College and a BS in biochemistry from University of New Hampshire.

Rosetta Biosoftware has created a scientific advisory board. Members include Ruedi Aebersold, Ronald Hendrickson, and Yoshiya Oda.
 
Aebersold is a professor at the Swiss Institute of Technology and the University of Zurich, and is a co-founder and current faculty member of the Institute for Systems Biology in Seattle.
 
Hendrickson is the director of proteomics in the department of molecular profiling at Merck Research Laboratories in Rahway, NJ. Before joining Merck he was chairman of the MDS Proteomics-Harvard Partners Joint Steering Committee.
 
Oda is a senior scientist at the Laboratory of Seeds Finding Technology at Japan’s Eisai, and a visiting associate professor at the Metabolome Laboratory at the University of Tokyo.

VisEn Medical has appointed Markus Rudin to its scientific advisory board. Rudin is professor of molecular imaging and functional pharmacology at both the University of Zürich and the Swiss Federal Institute of Technology. He formerly was head of imaging technologies at Novartis
 
In a related announcement, VisEn said Rudin's lab at the Swiss Federal Institute of Technology has adopted its portfolio of in vivo fluorescence probes and fluorescence molecular tomography imaging system for its molecular imaging programs.

Orchid Cellmark last week said that Gordon Wasserman has resigned from its board Aug. 18. The company did not provide a reason.

Caliper Life Sciences has hired Peter Lassota as divisional vice president of oncology. He joins Caliper from the Novartis Institutes for Biomedical Research where he led Novartis' US oncology pharmacology unit.
 
Lassota joins Caliper after the company acquired Xenogen earlier this month. In his new role Lassota will build on Xenogen’s line of biophotonic imaging products.
 
Lassota has an MS in chemistry from the University of Warsaw and a PhD in biochemistry and biophysics from the Polish Academy of Sciences.

 
Peakadilly has appointed Jim Van Heusden to its board of directors. Van Heusden is a senior investment manager at GIMV, which participated in a second series A round of private equity financing that recently netted the company €8.5 million ($10.9 million).

 
Celera Genomics has hired Joel Jung as vice president of finance, effective immediately.
 
Jung has held several executive and senior positions with Chiron, including most recently vice president and treasurer. He has a BS from Purdue University and an MBA from the University of California, Berkeley.

 
A. Keith Dunker, professor of biochemistry and of molecular biology at Indiana University School of Medicine, has been appointed director of School of Informatics’ Bioinformatics Program at the Bloomington and IU-Purdue University Indianapolis campuses.
 
He will also continue as director of the Center for Computational Biology and Bioinformatics at the School of Medicine.   
 
Dunker replaces Gary Wiggins, adjunct professor, who was serving as interim director of the bioinformatics program. Wiggins will continue leading the school’s chemical informatics program.
 
Assistant professor Sun Kim will retain his position as associate director of the bioinformatics program at Bloomington. Malika Mahoui, assistant professor, will serve as interim associate director of bioinformatics at IUPUI.
 
Separately, IU appointed Trevor Heritage, senior vice president and chief scientific officer of Elsevier MDL, to the science informatics advisory board of the Indiana University School of Informatics.
 
Heritage is a former senior vice president at Tripos. He holds a PhD in organic chemistry from the University of Reading, England.
 
In 2002, Elsevier MDL and the School of Informatics established the Elsevier MDL Excellence in Informatics Fellowship, which provides funding support to deserving incoming or second-year graduate students pursuing degrees in chemical informatics or bioinformatics.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.